Display options
Cite
Gousias K, Voulgaris S, Vartholomatos G, et al. Prognostic value of the preoperative immunological profile in patients with glioblastoma. Surg Neurol Int. 2014;5:89doi: 10.4103/2152-7806.134104.
Gousias, K., Voulgaris, S., Vartholomatos, G., Voulgari, P., Kyritsis, A. P., & Markou, M. (2014). Prognostic value of the preoperative immunological profile in patients with glioblastoma. Surgical neurology international, 589. https://doi.org/10.4103/2152-7806.134104
Gousias, Konstantinos, et al. "Prognostic value of the preoperative immunological profile in patients with glioblastoma." Surgical neurology international vol. 5 (2014): 89. doi: https://doi.org/10.4103/2152-7806.134104
Gousias K, Voulgaris S, Vartholomatos G, Voulgari P, Kyritsis AP, Markou M. Prognostic value of the preoperative immunological profile in patients with glioblastoma. Surg Neurol Int. 2014 Jun 07;5:89. doi: 10.4103/2152-7806.134104. eCollection 2014. PMID: 25024889; PMCID: PMC4093739.
Copy Download .nbib Format: NLM
Share it on

Surg Neurol Int. 2014 Jun 07;5:89. doi: 10.4103/2152-7806.134104. eCollection 2014.

Prognostic value of the preoperative immunological profile in patients with glioblastoma.

Surgical neurology international

Konstantinos Gousias, Spiridon Voulgaris, Georgios Vartholomatos, Paraskevi Voulgari, Athanasios P Kyritsis, Markella Markou

Affiliations

  1. Department of Neurosurgery, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 53105, Germany ; Department of Neurosurgery, University Hospital of Ioannina, 45500, Greece.
  2. Department of Neurosurgery, University Hospital of Ioannina, 45500, Greece.
  3. Department of Haematology, University Hospital of Ioannina, 45500, Greece.
  4. Department of Rheumatology, University Hospital of Ioannina, 45500, Greece.
  5. Department of Neurology, University Hospital of Ioannina, 45500, Greece.
  6. Department of Psychiatry, Landschaftsverband Rheinland Klinik, Kaiser-Karl-Ring 20, Bonn, 53111, Germany.

PMID: 25024889 PMCID: PMC4093739 DOI: 10.4103/2152-7806.134104

Abstract

BACKGROUND: Aim of our study was to determine the predictive impact of certain serum immunological markers on overall survival (OS) in patients with glioblastoma multiforme (GBM).

METHODS: We assayed prospectively values of interleukin 2 (IL-2), immunoglobulin G (IgG), C4, CD3+, CD4+ and CD8+ cells via flow cytometry, enzyme-linked immunosorbent assay (ELISA) and radial immunodiffusion in preoperative sera of adult patients with de novo histologically confirmed supratentorial GBM. Kaplan-Meier method and Cox proportional hazards models were used to assess clinical, laboratory, and treatment prognostic factors for OS.

RESULTS: Twenty-six consecutive patients were identified with a mean age of 59.6 years. Median follow up was 12 months. Lower IL-2 values (<7.97 pg/ml vs. ≥7.97 pg/ml, P = 0.029) und CD4+ counts (<200 cells/μl vs. ≥200 cells/μl, P < 0.001) correlated significantly with a shorter OS. The independent prognostic relevance of CD4 + counts was confirmed by the multivariate analysis (HR = 0.010, 95% CI 0.001-0.226, P = 0.011). Further independent prognostic factors for OS were type of resection (resection vs. biopsy) and administration of radiotherapy (yes/no).

CONCLUSION: Preoperative values IL-2 and CD4+ cells in sera may carry a prognostic impact. Novel diagnostic models prior to histopathological confirmation may be used to predict prognosis of patients with GBM. Future studies should investigate whether targeting immune factors, such as CD4+ and IL-2, may improve the prognosis of patients with GBM.

Keywords: CD4+ cells; IL-2; glioblastoma multiforme; overall survival; serum

References

  1. J Neuroimmunol. 2010 Sep 14;226(1-2):136-42 - PubMed
  2. Surg Neurol Int. 2013;4:14 - PubMed
  3. Cancer Res. 2006 Mar 15;66(6):3294-302 - PubMed
  4. Medicina (Kaunas). 2007;43(7):548-54 - PubMed
  5. Surg Neurol Int. 2013;4:15 - PubMed
  6. Surg Neurol Int. 2012;3:19 - PubMed
  7. J Neuroimmunol. 1999 Dec;100(1-2):216-32 - PubMed
  8. Acta Neuropathol. 2010 Dec;120(6):707-18 - PubMed
  9. Br J Cancer. 2010 Sep 7;103(6):827-36 - PubMed
  10. Arq Neuropsiquiatr. 1999 Sep;57(3A):539-46 - PubMed
  11. J Neurosurg. 2007 Feb;106(2):299-305 - PubMed
  12. Int J Cancer. 2010 Jul 1;127(1):101-10 - PubMed
  13. J Neurosurg. 2010 May;112(5):997-1004 - PubMed
  14. J Neuroimmunol. 2013 Nov 15;264(1-2):84-90 - PubMed
  15. Cancer Res. 1988 Jun 1;48(11):2981-7 - PubMed
  16. Neuro Oncol. 2010 Jul;12(7):725-35 - PubMed
  17. Acta Neurochir (Wien). 2007 Mar;149(3):245-52; discussion 252-3 - PubMed
  18. Immunol Rev. 2008 Apr;222:70-100 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1423-6 - PubMed
  20. Cancer Gene Ther. 2002 May;9(5):464-9 - PubMed
  21. Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76 - PubMed
  22. J Clin Oncol. 2008 Sep 1;26(25):4189-99 - PubMed
  23. Arthritis Rheum. 1989 Jul;32(7):884-93 - PubMed
  24. Acta Neurol Scand. 2010 Sep;122(3):159-67 - PubMed
  25. Blood. 2009 May 21;113(21):5134-43 - PubMed
  26. Neuro Oncol. 2012 Aug;14(8):958-78 - PubMed
  27. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  28. Neuroepidemiology. 2009;33(2):89-95 - PubMed
  29. J Neurosurg. 2006 Sep;105(3):430-7 - PubMed

Publication Types